These findings imply that an anticancer CD8+ T cell response initiated in the shared tdLN achieves effective elimination of the PGE2-deficient tumour but nevertheless fails in the co-transplanted PGE2-producing tumour. The gene discussed is CD8A; the disease is neoplasm.